Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alteon (ALT) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. T. who wrote (166)	12/4/1997 11:43:00 AM
From: Bill Tomko	Read Replies (1) \| Respond to of 318

assuming ,which I personally think is a reasonably good bet, positive clinical findings in the summer of 1998, A fililing 4'th q 1998 or 1'st q 1999 commercial sales should begin 3'd to 4'th q 1999. This product COULD be a billion $ sales product. Additionaly cross link breakers could follow in 12 to 36 months. The Idexx labs animal use could begin in 1998 or early 1999. This could be a nice book of business. There is the potenial for lable cliam expansion to ESRD in 1999 or 2000. As you move into mid 1998 and ASSUMEING good clinical findings the market will begin to reflect the sales potenial. Look at CNTO price as repro began to approach the market. This is a reasonably cheap stock

To: Dr. T. who wrote (166)	12/4/1997 1:12:00 PM
From: Mac S. Giballa	Read Replies (1) \| Respond to of 318

1998 will close out the big studies- ACTION I and ESRD. All indications look good. Remember this drug is potentially huge, in animal studies it can keep diabetics from developin most complications such as kidney disease and blindness. Every diabetic in the world could eventually end up on it, which would make the largest selling drug in history by far. Of course this is an absolutely best case scenario, but given the potential- at $20 a share the market cap is still only $300 million. Centocor has a cap of $3 billion with a drug that sells only $240 million.